431 reports of this reaction
2.1% of all ASENAPINE MALEATE reports
#9 most reported adverse reaction
SEXUAL DYSFUNCTION is the #9 most commonly reported adverse reaction for ASENAPINE MALEATE, manufactured by Allergan, Inc.. There are 431 FDA adverse event reports linking ASENAPINE MALEATE to SEXUAL DYSFUNCTION. This represents approximately 2.1% of all 20,068 adverse event reports for this drug.
Patients taking ASENAPINE MALEATE who experience sexual dysfunction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEXUAL DYSFUNCTION is a less commonly reported adverse event for ASENAPINE MALEATE, but still significant enough to appear in the safety profile.
In addition to sexual dysfunction, the following adverse reactions have been reported for ASENAPINE MALEATE:
The following drugs have also been linked to sexual dysfunction in FDA adverse event reports:
SEXUAL DYSFUNCTION has been reported as an adverse event in 431 FDA reports for ASENAPINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEXUAL DYSFUNCTION accounts for approximately 2.1% of all adverse event reports for ASENAPINE MALEATE, making it a notable side effect.
If you experience sexual dysfunction while taking ASENAPINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.